The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).
Marta Schirripa
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Manfredi Morvillo
No relevant relationships to disclose
Francesca Bergamo
No relevant relationships to disclose
Federica Zoratto
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Federica Marmorino
No relevant relationships to disclose
Elisa Sensi
No relevant relationships to disclose
Cristiana Lupi
No relevant relationships to disclose
Gabriella Fontanini
No relevant relationships to disclose
Veronica De Gregorio
No relevant relationships to disclose
Riccardo Giannini
No relevant relationships to disclose
Fulvio Basolo
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose